|
RGLS | Regulus Therapeutics Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.34 |
| Leverage | 8.78% |
| Market Cap | $ 165.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -47.4m |
| Margin | 0.00% |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The company is headquartered in San Diego, California.